1. CLEC5a-directed bispecific antibody for effective cellular phagocytosis
- Author
-
Vivekananda Kedage, Diego Ellerman, Mingjian Fei, Wei-Ching Liang, Gu Zhang, Eric Cheng, Juan Zhang, Yongmei Chen, Haochu Huang, Wyne P. Lee, Yan Wu, and Minhong Yan
- Subjects
Phagocytosis ,bispecific antibody ,CLEC5A ,Fcγ receptor ,treg ,tumor-associated macrophage ,Therapeutics. Pharmacology ,RM1-950 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
While antibody-dependent cellular phagocytosis mediated by activating Fcγ receptor is a key mechanism underlying many antibody drugs, their full therapeutic activities can be restricted by the inhibitory Fcγ receptor IIB (FcγRIIB). Here, we describe a bispecific antibody approach that harnesses phagocytic receptor CLEC5A (C-type Lectin Domain Containing 5A) to drive Fcγ receptor-independent phagocytosis, potentially circumventing the negative impact of FcγRIIB. First, we established the effectiveness of such an approach by constructing bispecific antibodies that simultaneously target CLEC5A and live B cells. Furthermore, we demonstrated its in vivo application for regulatory T cell depletion and subsequent tumor regression.
- Published
- 2022
- Full Text
- View/download PDF